Outcomes of an enhanced recovery after surgery (ERAS) protocol following head and neck cancer surgery with free flap reconstruction
International Journal of Oral and Maxillofacial Surgery · 2026-02 · 55 (2) · 143-151
DOI: 10.1016/j.ijom.2025.08.005 ↗Kurz gefasst
Studienprotokoll in der Zeitschrift International Journal of Oral and Maxillofacial Surgery, 2026-02. Verfasst von G Raj und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oral and Maxillofacial Surgery, National Dental Centre Singapore, Singapore. Hauptthemen laut MEDLINE: Free Tissue Flaps, Head and Neck Neoplasms, Plastic Surgery Procedures, Enhanced Recovery After Surgery. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 48 Literaturangaben.
Abstract (Originalsprache)
The aim of this study was to evaluate the effectiveness of an enhanced recovery after surgery (ERAS) protocol following head and neck cancer (HNC) surgery with free flap reconstruction. Primary outcomes measured were length of stay (LOS), days to oral feeds, days to ambulation, complications within 1 month, and 30-day readmission. Secondary outcomes included days to urinary catheter removal (TOC), use and duration of patient-controlled analgesia (PCA), days to decannulation, and days to radiation therapy. Seventy-nine patients were studied: 37 ERAS and 42 pre-ERAS, with comparable baseline demographics. The ERAS group demonstrated significantly shorter median days to oral feeds (8.0 vs 11.0, P = 0.045) and TOC (5.0 vs 11.0, P = 0.007). Respiratory complications were also significantly lower in the ERAS group (0% vs 16.7%, P = 0.009). However, the ERAS group had longer median days to decannulation (8.0 vs 5.0, P < 0.001). No significant differences were observed in LOS, overall complication rate, or 30-day readmission. Adoption of the ERAS protocol in HNC free flap reconstruction is safe and effective, reducing time to oral feeding, respiratory complications, and days to TOC, though with longer decannulation times, without adversely affecting overall complications or readmissions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Oral and Maxillofacial Surgery, National Dental Centre Singapore, Singapore.
- Department of Plastic, Reconstructive and Aesthetic Surgery, Singapore General Hospital, Singapore.
- Department of Head and Neck Surgery, Division of Surgery and Surgical Oncology, National Cancer Centre Singapore and Singapore General Hospital, Singapore.
- Department of Oral and Maxillofacial Surgery, National Dental Centre Singapore, Singapore; Department of Head and Neck Surgery, Division of Surgery and Surgical Oncology, National Cancer Centre Singapore and Singapore G…
- Department of Head and Neck Surgery, Division of Surgery and Surgical Oncology, National Cancer Centre Singapore and Singapore General Hospital, Singapore. Electronic address: angela.renayanti.dharmawan@singhealth.com.s…
Zitieren
APA
Raj, G., Raj, M., Ng, H. H. M., Suh, J., Shannon, N. B., Nagadia, R. H., Iyer, N. G., & Dharmawan, R. (2026). Outcomes of an enhanced recovery after surgery (ERAS) protocol following head and neck cancer surgery with free flap reconstruction. International Journal of Oral and Maxillofacial Surgery, 55(2), 143-151. https://doi.org/10.1016/j.ijom.2025.08.005
Vancouver
Raj G, Raj M, Ng HHM, Suh J, Shannon NB, Nagadia RH, et al. Outcomes of an enhanced recovery after surgery (ERAS) protocol following head and neck cancer surgery with free flap reconstruction. International Journal of Oral and Maxillofacial Surgery. 2026;55(2):143-151. doi:10.1016/j.ijom.2025.08.005
BibTeX
@article{Raj2026,
author = {Raj, G and Raj, M and Ng, H H M and Suh, Jimin and Shannon, N B and Nagadia, R H and Iyer, N G and Dharmawan, R},
title = {Outcomes of an enhanced recovery after surgery (ERAS) protocol following head and neck cancer surgery with free flap reconstruction},
journal = {International Journal of Oral and Maxillofacial Surgery},
year = {2026},
volume = {55},
number = {2},
pages = {143--151},
doi = {10.1016/j.ijom.2025.08.005}
}
EUVIMED